X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (44) 44
humans (40) 40
human necessities (39) 39
hygiene (39) 39
medical or veterinary science (39) 39
preparations for medical, dental, or toilet purposes (39) 39
cardiovascular (38) 38
male (37) 37
female (35) 35
cardiac & cardiovascular systems (34) 34
internal medicine (33) 33
aged (31) 31
middle aged (31) 31
percutaneous coronary intervention (31) 31
cangrelor (30) 30
clopidogrel (28) 28
heart attacks (24) 24
adenosine monophosphate - analogs & derivatives (23) 23
treatment outcome (22) 22
platelet inhibition (20) 20
bivalirudin (19) 19
cardiac patients (19) 19
thrombosis (19) 19
transluminal angioplasty (19) 19
ticlopidine - analogs & derivatives (18) 18
double-blind method (17) 17
myocardial infarction (17) 17
stents (17) 17
abridged index medicus (15) 15
adenosine monophosphate - administration & dosage (15) 15
risk factors (15) 15
acute coronary syndromes (14) 14
adenosine monophosphate - adverse effects (14) 14
ischemia (14) 14
mortality (14) 14
platelet aggregation inhibitors - administration & dosage (14) 14
stent thrombosis (14) 14
time factors (14) 14
cardiology and cardiovascular medicine (13) 13
pci (13) 13
percutaneous coronary intervention - adverse effects (13) 13
care and treatment (12) 12
hemorrhage - chemically induced (12) 12
patients (12) 12
ticlopidine - administration & dosage (12) 12
agriculture (11) 11
animal husbandry (11) 11
antiplatelet therapy (11) 11
biocides, e.g. as disinfectants, as pesticides, as herbicides (11) 11
cardiology (11) 11
clinical trials (11) 11
fishing (11) 11
forestry (11) 11
hunting (11) 11
pest repellants or attractants (11) 11
plant growth regulators (11) 11
preservation of bodies of humans or animals or plants or partsthereof (11) 11
trapping (11) 11
usage (11) 11
coronary vessels (10) 10
drug therapy (10) 10
odds ratio (10) 10
platelet aggregation inhibitors - adverse effects (10) 10
purinergic p2y receptor antagonists - administration & dosage (10) 10
ticagrelor (10) 10
anticoagulants (9) 9
dose-response relationship, drug (9) 9
elevation myocardial-infarction (9) 9
management (9) 9
myocardial infarction - therapy (9) 9
platelet aggregation inhibitors - therapeutic use (9) 9
specific therapeutic activity of chemical compounds ormedicinal preparations (9) 9
ticlopidine - adverse effects (9) 9
adult (8) 8
bleeding (8) 8
cardiovascular disease (8) 8
coronary thrombosis - etiology (8) 8
dosage and administration (8) 8
heart attack (8) 8
medical colleges (8) 8
medicine & public health (8) 8
prasugrel (8) 8
acute myocardial-infarction (7) 7
adenosine monophosphate - therapeutic use (7) 7
angina pectoris (7) 7
angioplasty (7) 7
chi-square distribution (7) 7
myocardial infarction - etiology (7) 7
myocardial-infarction (7) 7
outcomes (7) 7
peptide fragments - therapeutic use (7) 7
prospective studies (7) 7
purinergic p2y receptor antagonists - adverse effects (7) 7
recombinant proteins - therapeutic use (7) 7
united states - epidemiology (7) 7
analysis (6) 6
confidence intervals (6) 6
follow-up studies (6) 6
hemorrhage (6) 6
implants (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2013, Volume 369, Issue 23, pp. 2207 - 2217
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1303 - 1313
This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | TICAGRELOR | CARDIOVASCULAR EVENTS | ACHIEVE OPTIMAL MANAGEMENT | CLOPIDOGREL PRETREATMENT | PRASUGREL | STANDARD THERAPY | ANTIPLATELET THERAPY | STRATEGIES | Double-Blind Method | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Adenosine Monophosphate - analogs & derivatives | Hemorrhage - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Ticlopidine - adverse effects | Female | Aged | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Stents - adverse effects | Thrombosis - mortality | Platelet Aggregation Inhibitors - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Cangrelor | Angioplasty | Patient outcomes | Product/Service Evaluations | Hemorrhage | Risk factors | Control | Ischemia | Dosage and administration | Drug therapy | Myocardial infarction | Adenosine | Heart attacks | Intravenous administration | Thrombosis | Patients | Bleeding | Dyspnea | Implants | Clopidogrel | Acute coronary syndromes | Respiration
Journal Article
JAMA, ISSN 0098-7484, 01/2012, Volume 307, Issue 3, pp. 265 - 274
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 13, pp. 200 - 200
  Conclusions In patients referred for invasive evaluation and treatment of coronary artery disease, pretreatment rates with P2Y12 inhibitors are low, even... 
Cardiovascular | Internal Medicine | Coronary heart disease | Cardiovascular disease | Medical imaging | Angina pectoris | Coronary vessels
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 2, pp. 176 - 185
Abstract Background Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention... 
Cardiovascular | Internal Medicine | coronary artery disease | bleeding | antiplatelet therapy | outcomes | CARDIAC & CARDIOVASCULAR SYSTEMS | PRIMARY PCI | BIVALIRUDIN | IMPAIRED BIOAVAILABILITY | CHAMPION PHOENIX | CLOPIDOGREL | PLATELET INHIBITION | BLOOD-TRANSFUSION | ELEVATION MYOCARDIAL-INFARCTION | INSIGHTS | Prospective Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Aspirin - adverse effects | Ticlopidine - adverse effects | Female | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Angioplasty, Balloon, Coronary - methods | Myocardial Ischemia - prevention & control | Treatment Outcome | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Adenosine Monophosphate - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Cohort Studies | Transluminal angioplasty | Continuing medical education | Cardiac patients | Medical care | Research institutes | Cardiology | Quality management | Heart attacks | Mortality | Thrombosis | Patients | Studies | Consortia | Ischemia | Coronary vessels | Bailouts | Intubation | Acute coronary syndromes | Stents | Drug dosages | Veins & arteries
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2014, Volume 63, Issue 7, pp. 619 - 629
Journal Article
American Heart Journal, ISSN 0002-8703, 2017, Volume 188, pp. 147 - 155
Objective To examine the safety and efficacy of cangrelor in patients with single-vessel disease (SVD) and multi-vessel disease (MVD). Background Cangrelor, an... 
Cardiovascular | IMPACT | CARDIAC & CARDIOVASCULAR SYSTEMS | PRACTICE GUIDELINES | MANAGEMENT | PLATELET INHIBITION | ACUTE MYOCARDIAL-INFARCTION | AMERICAN-COLLEGE | ELEVATION | ASSOCIATION TASK-FORCE | ANTIPLATELET THERAPY | STRATEGIES | Myocardial Infarction - epidemiology | Purinergic P2Y Receptor Antagonists - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Postoperative Complications - prevention & control | Male | Incidence | Dose-Response Relationship, Drug | Time Factors | Ticlopidine - administration & dosage | Female | Survival Rate - trends | Double-Blind Method | Global Health | Administration, Oral | Postoperative Complications - epidemiology | Ticlopidine - analogs & derivatives | Coronary Angiography | Coronary Artery Disease - therapy | Coronary Artery Disease - diagnosis | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Cause of Death - trends | Aged | Myocardial Infarction - prevention & control | Infusions, Intravenous | Percutaneous Coronary Intervention | Transluminal angioplasty | Medicine, Experimental | Medical research | Care and treatment | Cardiac patients | Myocardial infarction | Intervention | Surgical implants | Intravenous administration | Heart attacks | Laboratories | Angioplasty | Clinical trials | Cardiovascular disease | Grafting | Bleeding | Clinical outcomes | Consortia | Ischemia | Blood platelets | Motivation | Risk assessment | Implants | Electrocardiography | Safety | Thromboembolism | Stents | Drug dosages | Hypertension | Anticoagulants | Cerebral infarction | Stroke | Effectiveness | Adjustment | Hyperlipidemia | Complications | Mortality | Diabetes mellitus | Coronary artery | Angina pectoris | Patients | Thrombosis | Coronary vessels | Clopidogrel | Death | Infarction | Acute coronary syndromes | Bypasses
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 15, pp. 1846 - 1857
The risk of recurrent ischemic and bleeding events after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction... 
percutaneous coronary intervention | ischemic events | ST-segment elevation myocardial infarction | average daily rate | bleeding events | HARMONIZING OUTCOMES | TRIAL | BIVALIRUDIN | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | DUAL ANTIPLATELET THERAPY | STENT THROMBOSIS | HEART-FAILURE | PLATELET INHIBITION | ACUTE MYOCARDIAL-INFARCTION | UNFRACTIONATED HEPARIN | Risk Assessment - methods | United States - epidemiology | Postoperative Hemorrhage - prevention & control | Humans | Middle Aged | Postoperative Hemorrhage - diagnosis | Male | Aspirin - administration & dosage | Time Factors | Aspirin - adverse effects | Percutaneous Coronary Intervention - methods | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - diagnosis | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Postoperative Hemorrhage - epidemiology | Myocardial Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Postoperative Hemorrhage - etiology | ST Elevation Myocardial Infarction - mortality | Myocardial Ischemia - etiology | ST Elevation Myocardial Infarction - surgery | Clopidogrel | Percutaneous Coronary Intervention - statistics & numerical data | Aged | Stents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Transluminal angioplasty | Coronary heart disease | Risk factors | Myocardial infarction | Surgical implants | Adenosine | Aspirin | Heart attacks | Mortality | Coronary artery | Risk | Patients | Thrombosis | Thrombolysis | Bleeding | Confidence intervals | Ischemia | Implants | Infarction | Mathematical models | Clinical medicine | Acute coronary syndromes | Thromboembolism | Heart diseases | Stents
Journal Article